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Background: Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular
endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor
receptor α (PDGFR α), RET and KIT. Antiangiogenesis activity of lenvatinib in VEGF- and FGF-driven angiogenesis
models in both in vitro and in vivo was determined. Roles of tumor vasculature (microvessel density (MVD) and
pericyte coverage) as biomarkers for lenvatinib were also examined in this study.
Method: We evaluated antiangiogenesis activity of lenvatinib against VEGF- and FGF-driven proliferation and tube
formation of HUVECs in vitro. Effects of lenvatinib on in vivo angiogenesis, which was enhanced by overexpressed
VEGF or FGF in human pancreatic cancer KP-1 cells, were examined in the mouse dorsal air sac assay. We
determined antitumor activity of lenvatinib in a broad panel of human tumor xenograft models to test if vascular
score, which consisted of high MVD and low pericyte coverage, was associated with sensitivity to lenvatinib treatment.
Vascular score was also analyzed using human tumor specimens with 18 different types of human primary tumors.
Result: Lenvatinib inhibited VEGF- and FGF-driven proliferation and tube formation of HUVECs in vitro. In vivo
angiogenesis induced by overexpressed VEGF (KP-1/VEGF transfectants) or FGF (KP-1/FGF transfectants) was significantly
suppressed with oral treatments of lenvatinib. Lenvatinib showed significant antitumor activity in KP-1/VEGF and five 5
of 7 different types of human tumor xenograft models at between 1 to 100 mg/kg. We divided 19 human tumor
xenograft models into lenvatinib-sensitive (tumor-shrinkage) and relatively resistant (slow-growth) subgroups based on
sensitivity to lenvatinib treatments at 100 mg/kg. IHC analysis showed that vascular score was significantly higher in
sensitive subgroup than relatively resistant subgroup (p < 0.0004). Among 18 types of human primary tumors, kidney
cancer had the highest MVD, while liver cancer had the lowest pericyte coverage, and cancers in Kidney and Stomach
had highest vascular score.
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Conclusion: These results indicated that Lenvatinib inhibited VEGF- and FGF-driven angiogenesis and showed a broad
spectrum of antitumor activity with a wide therapeutic window. MVD and pericyte-coverage of tumor vasculature
might be biomarkers and suggest cases that would respond for lenvatinib therapy.
Keyword: Lenvatinib, VEGFR2 kinase inhibitor, FGFR kinase inhibitor, Pericyte coverage, Microvessel densityBackground
Angiogenesis, the formation of new blood vessels, has
physiologic and pathologic roles [1]. RTK signaling path-
ways have been identified as crucial regulators of angiogen-
esis, including the signaling pathways of VEGFR, FGFR,
HGFR, PDGFR, TIE2 and EPH expressed in endothelial
or vascular mural cells [1]. The VEGF-signaling pathway
is the key regulator of tumor growth and metastasis
and consists of five ligands (VEGFA-D and placental
growth factor (PlGF)) and three RTKs (VEGFR1, VEGFR2,
VEGFR3) [2]. Bevacizumab (a monoclonal antibody
against VEGFA) was the first angiogenesis inhibitor, and
was approved for the treatment of patients with metastatic
colon cancer based on its survival benefit [3]. It is also
used to treat non-small cell lung cancer (NSCLC), renal
cell carcinoma (RCC), glioblastoma multiforme (GBM)
and breast cancer [4]. The use of bevacizumab confirmed
that blocking the VEGF-signaling pathway is a feasible ap-
proach to cancer therapy.
VEGFR2 induces major phenotypic changes of endothe-
lial cells in angiogenesis, including proliferation, migration,
survival, and tube formation [5-7]. Several small-molecule
inhibitors of VEGFR2 kinase have been approved for treat-
ments of multiple cancer types, such as sunitinib (RCC,
gastrointestinal stromal tumor (GIST)) [8,9], sorafenib
(RCC, HCC, differentiated thyroid cancer (DTC)) [10-12],
pazopanib (RCC, soft-tissue sarcoma (STS)) [13,14], axi-
tinib (RCC) [15], vandetanib (medullary thyroid cancer
(MTC)) [16] and regorafnib (colorectal cancer (CRC),
GIST) [17,18]. The approved indications for bevacizumab
and VEGFR2 tyrosine kinase inhibitor (TKI) are similar
for CRC and RCC, but different for breast cancer, HCC,
NSCLC, GBM, DTC, MTC and STS. Among the five li-
gands of the VEGF-signaling pathway (VEGFA-D and
PIGF), bevacizumab targets only VEGFA. VEGFR1 pre-
dominantly mediates chemotactic activity in monocytes
and macrophages [19], and mobilization of bone-marrow-
derived endothelial and hematopoietic stem cells [20].
VEGFR3 is expressed by the lymphatic endothelium and
promotes tumor lymphangiogenesis and tumor spread
through lymphatic vessels [21]. Thus, the inhibition of
signal transduction via multiple VEGFRs may be a
promising therapeutic strategy. The development of
novel inhibitors of multi-targeted RTKs in addition to
VEGFR2 is still required to improve cancer therapy inthe clinic [22], since one of the resistance mechanisms in-
volved is the up-regulation of alternative pro-angiogenic
signaling pathways that include FGF/FGFR, angiopoie-
tin/TIE2 and ephrin/EPH [23].
Antiangiogenesis therapy with antibody against VEGF
or inhibitors of multiple RTKs targeting VEGFR2 im-
proves the survival of patients with a variety of advanced
cancers. However, the durations of treatment are limited
due to acquired resistance, and sub-groups of patients
do not respond due to intrinsic resistance [23]. Surro-
gate biomarkers of those angiogenesis inhibitors might
help improve the selection of appropriate patients and
contribute to decisions regarding whether to continue
antiangiogenesis therapy. The biomarkers for identifying
responsive patients for antiangiogenesis therapy included
plasma proteins [24], circulating endothelial cells [25,26],
and novel imaging techniques [27], but no reliable pre-
dictive biomarkers have been established. Interactions
between endothelial cells and vascular mural cells (e.g.,
pericytes) have been studied and in light of the finding
that bevacitzumab increased the numbers of pericyte-
covered vessels after one-shot treatment for human
colorectal cancer [28,29], it is likely that the extent of
the interaction of tumor endothelial cells with pericytes
is relevant to the responsiveness to antiangiogenesis
therapy. However it has not been proven yet that those
interactions predict antitumor activity of antiangiogen-
esis therapy. Examinations of these interactions would
thus be important in the development of predictive bio-
markers for antiangiogenesis therapy in both preclinical
and clinical cancer.
We previously reported a novel multi-targeted VEGFR2
TKI, lenvatinib (E7080), which inhibited KIT-dependent
angiogenesis [26] and VEGFR3-related lymphangiogenesis
[30]. Lenvatinib showed the activity against multiple types
of cancer in a phase I study [25,31] and phase II/III clinical
studies in patients with such cancers as DTC, MTC, HCC,
melanoma, and endometrial cancer are currently in pro-
gress. In this study, we investigated the pharmacologic
profile of lenvatinib and we determine the antiangiogen-
esis activity in VEGF- and FGF-driven angiogenesis assays.
Next, antitumor activity of lenvatinib was explored in a
panel of various human tumor xenograft models in order
to identify biomarkers for predicting the response to
lenvatinib. MVD and pericyte coverage were determined
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lar score analysis as candidate biomarkers and an associ-
ation of vascular score with the antitumor activity of
lenvatinib was analyzed. In addition, mRNA expression
levels of genes related to angiogenesis by qPCR were cor-
related with antitumor activity of lenvatinib. Lastly vascu-
lar score analysis was also performed using human tumor
tissue specimens, if vascular score is able to identify tumor
vascular phenotypes of human cancer.
Materials and methods
Chemical synthesis of lenvatinib
The chemical name of lenvatinib is [4-[3-Chloro-4-
(N’-cyclopropylureido)phenoxy]-7-methoxyquinoline-
6-carboxamide], and the structural formula is shown in
Figure 1A. The compound was synthesized by Eisai Co.,
Ltd., and its chemical identity was established by nuclear
magnetic resonance and mass spectroscopy.
Cell lines
Tumor cell lines were purchased from the American
Type Culture Collection (Rockville, MD), except for hu-
man pancreatic tumor KP-1 and FEM cells, which were
from the National Kyusyu Cancer Center (Fukuoka,
Japan) and Prof. Ostein Fodstad at Norwegian RadiumFigure 1 Kinase inhibitory activity and antiangiogenic activity of lenv
lenvatinib. C: Effects of lenvatinib on the VEGF-induced proliferation and tu
and tube formation of HUVEC. sTF assay; sandwich tube formation assay.Hospital Research Foundation, respectively. KP-1 trans-
fectants were prepared by stable transfection (Effecten
transfection reagent; Qiagen, Tokyo, Japan) of pcDNA3.1
vectors (Life technologies, Tokyo, Japan) coding either
human VEGF121 (KP-1/VEGF) or mouse FGF4 (KP/
FGF) into KP-1 cells and selected by G418 (Life tech-
nologies). VEGF121 lacks a heparin binding site and is
therefore more diffusible than VEGF165. FGF4 has a sig-
nal peptide, but FGF1 and FGF2 do not. Therefore, we se-
lected VEGF121 and FGF4 for overexpression in this
study, since in vivo angiogenesis in Dorsal Air Sac (DAS)
assay is driven by secreted angiogenic factors from tumor
cells packed into the Millipore chambers. Tumor cell lines
were maintained in RPMI1640 medium containing 10%
heat-inactivated fetal bovine serum (FBS). Human umbil-
ical vein endothelial cells (HUVECs) were isolated from a
human umbilical cord by a method described previously
[32] and cultured using an EGM-2 BulletKit (Sanko
Junyaku, Tokyo, Japan).Animals
Balb/c nude mice (Charles River Laboratories, Yokohama,
Japan) were used for human tumor xenograft models.
Animal experiments were conducted in accordance withatinib in vitro. A: Chemical structure of lenvatinib. B: Ki values of
be formation of HUVEC. D: Effects on the FGF-induced proliferation
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guidelines of Eisai Co., Ltd.
In vitro kinase assay
Tyrosine kinase assays were performed by an ELISA and
Off-chip Mobility Shift Assay (MSA) by Carna Biosciences,
Inc. (Kobe, Japan).
Proliferation assay
Tumor cells were plated at 1 to 2 × 103 cells/well on 96-
well plates in 0.1 ml of RPMI 1640 containing 10% FBS.
After 24 h, lenvatinib or vehicle was added, and 2 or 3 days
after drug treatments, The ratios of surviving cells were
calculated by measuring the absorbance of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in
each well and expressing it relative to the absorbance in the
control wells. The HUVEC proliferation assay were per-
formed by a method described previously [32]. Briefly,
HUVECs were seeded on type I-collagen coated 96-well
plates at 0.6 × 103 cells with serum free medium (SFM)
(Invitrogen, Carlsbad, CA) containing 2% FBS (2% FBS-
SFM) and an aliquot of lenvatinib with VEGF (Genzyme,
Cambridge, MA) or FGF2 (Sigma-Aldrich, St. Louis, MO)
(20 ng/mL) in 2% FBS-SFM was added. After incubation for
3 days, cell viability was determined by measuring the ab-
sorbance of WST-1 reagent (DOJINDO, Kumamoto, Japan).
Percent inhibition of cell growth was determined by the for-
mula below: Inhibition (%) =Mean value of OD of control
wells - OD of treated wells * 100/Mean value of OD of con-
trol wells. Each value is expressed as the mean. An IC50
value was determined from the curves representing growth
inhibition activity versus lenvatinib concentration. All exper-
iments were done in either duplicate or quadruplicate.
In vitro angiogenesis assay
In vitro sandwich tube formation (sTF) assay, HUVECs in
SFM containing EGF (10 ng/mL) with VEGF (20 ng/mL)
or FGF2 (20 ng/ml) were plated onto the 1st layer of colla-
gen gel (Nitta Gelatin, Tokyo, Japan) at 1.0 × 105 cells in
24-well plates and a 2nd layer of collagen gel was added
onto the HUVECs. An aliquot of lenvatinib in SFM con-
taining EGF with VEGF- or FGF2 was added at the indi-
cated dose. After 4 days, MTT solution was added and
photomicrographs of tube formation were taken with a
light microscope. The tube length of capillaries was
measured using image analysis (Angiogenesis Image
Analyzer, ver. 1.04; Kurabo, Osaka, Japan).
Mouse dorsal air sac (DAS) assay
An in vivo angiogenesis assay in mice was performed as
described previously [32] with minor changes. Millipore
chambers (Millipore, Bedford, MA) were packed with 1.0
× 107 KP-1 mock, KP-1/VEGF or KP-1/FGF transfectants
and transplanted into the dorsal air sac of C57BL/6 mice(n = 3–5 each, with experiments performed in tripli-
cate). For a pseudo-operation, collagen I gel was
injected into the Millipore chambers. Photographs were
taken 4 days after implantation.Subcutaneous (s.c.) xenograft models
Tumor cells were injected subcutaneously into the right
flank region of 7-week-old nude mice. When the mean
tumor volume reached approximately 100–300 mm3,
tumor-bearing mice were randomized and the adminis-
tration of either vehicle or lenvatinib was started (day 1).
Tumor diameters were measured with a vernier caliper
and body weight was measured twice weekly. The tumor
volume (mm3) was calculated using the formula: length
(mm) × width (mm)2 × 1/2. The antitumor activity of
lenvatinib was calculated as a ΔT/C (% of control for
Δgrowth) after the administration period. ΔT/C was
calculated according to the formula: (ΔT/ΔC) × 100. ΔT
and ΔC are the changes in tumor volume (Δgrowth) for
the treated and vehicle/control groups, respectively. When
the tumor volume was reduced, the ΔT/C values were cal-
culated by the following formula: ΔT/C (%) = (TVn −
TV1)/TV1 × 100, where TVn is the tumor volume of
treated mice at day n. The number of mice is ten for con-
trol group in Table 1 and five for each group in other ex-
periments. Mice in control group were treated with
vehicle.IHC analysis of MVD and pericyte coverage
We defined pericyte-covered vessels as endothelial cells
were fully surrounded or partially surrounded by αSMA
positive cells as described previously [33,34]. Briefly,
8-μm frozen sections were fixed with cold acetone and
immunostained with rat anti-mouse CD31 monoclonal
antibody (BD Biosciences, Franklin Lakes, NJ) and mouse
anti-α-SMA monoclonal antibody (Sigma-Aldrich) by
the ABC and LSAB methods using a Vectastain ABC
kit (Funakoshi, Tokyo, Japan) and LSAB kit (Dako,
Glostrup, Denmark). Adjacent sections were routinely
stained with hematoxylin and eosin. All histologi-
cal specimens were viewed under a CCD Hyper Scope
(Keyence, Osaka, Japan) and analyzed using Image Tool
software (Image Tool, Roswell, GA). MVD was deter-
mined as the mean of four or five fields per cross-section.
Pericyte coverage was calculated based on the ratio of
the double-staining vessels per total vessel count in the
hotspot areas. Human tumor specimens were purchased
from SuperBioChips (Seoul, South Korea). The human
tumor specimens were double-stained with mouse anti-
human CD31 monoclonal antibody (Dako) and alkaline
phosphatase-labeled mouse anti-α-SMA monoclonal anti-
body (Sigma-Aldrich) using an Envision HRP kit (Dako)
and the LSAB kit.
Table 1 Summary of antitumor activity of lenvatinib in seven subcutaneous xenograft models
Tumor cell IC50
1) (μM) TV2) (mm3)
ΔTV (%)3) lenvatinib (mg/kg)
1 3 10 30 100
MDA-MB 4354) (Melanoma) 24.2 180 55.7* 56.9* 40.2* 21.2* 25.7*
MIApaca-II5) (Pancreas) 33.8 250 56.1* 49.9* 30.1* 15.3* 12.5*
H4605) (Lung) 26.3 110 65.4 34.9* 16.3* 16.4* −0.8*
SK-OV-35) (Ovary) 26.4 230 52.3* 39.6* 12.2* 8.3* −15.6*
Colo2055) (Colon) 27.5 320 43.8* 23.1* 12.8* −4.5* −21.3*
A4315) (Epidermoid) 30.8 310 41.7 29.4* 0.0* −7.5* −32.9*
DU1454) (Prostate) 30.8 160 −7.5* −42.2* −65.4* −72.0* −78.6*
1)In vitro anti-proliferative activity of lenvatinib.
2)Lenvatinib treatments started at indicated tumor volumes.
3)ΔT/C of individual mice was determined first, and then an mean value was calculated.
4)Lenvatinib was orally administered twice daily for 28 days.
5)Lenvatinib was orally administered twice daily for 14 days.
*p < 0.05 versus vehicle control.
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Total RNA was isolated from xenografted tumors at a
size of approximately 100–300 mm3 using an RNeasy kit
(Qiagen, Valencia, CA). Reverse transcription was per-
formed for 59 genes related to angiogenesis using
Multiscribe™ Reverse Transcriptase (Invitrogen), and
the quantitative real-time polymerase chain reaction
(qPCR) analysis was performed using a TaqMan® Low-
Density Array (Invitrogen) (Additional file 1).
Statistical analysis
For the statistical analysis of the activity in the s.c. xeno-
graft models and mouse DAS models, a repeated mea-
sures analysis of variance (ANOVA) was used, followed
by a Dunnett-type multiple comparison test. Statistical
analyses for MVD and % of pericyte coverage were per-
formed by student t-test and vascular score analysis was
performed by Wilcoxon test. Correlative analysis of
mRNA with ΔT/C was performed by Spearman’s rank
correlation test and association with sensitivity was done
by Mann–Whitney u test. Results were considered sig-
nificant at p < 0.05.
Results
Kinase inhibitory profile and effects of lenvatinib in
in vitro VEGF- and FGF-driven proliferation and tube
formation of HUVEC
Lenvatinib is a novel quinoline derivative containing an aryl
urea moiety (Figure 1A). The kinase inhibitory profile of
lenvatinib was determined by biochemical kinase assays for
tyrosine kinases (Figure 1B). Lenvatinib strongly inhibited
VEGFR1, 2, 3 RTK (Ki = 1.3, 0.74, 0.71 nM, respectively),
and also exhibited inhibitory activities against FGFR1, 2, 3
RTK (Ki = 22, 8.2, 15 nM, respectively) in addition to RET
and KIT (Ki = 1.5 and 11nM, respectively). We previ-
ously reported that lenvatinib inhibited angiogenesisthrough activated KIT [26]. Since lenvatinib showed an
equivalent inhibition against FGFR RTK to KIT, we de-
termined effects of lenvatinib on HUVECs stimulated
with FGF-2 besides VEGF. Lenvatinib inhibited VEGF-
induced proliferation and tube formation of HUVECs
with IC50 values of 3.4 and 2.7 nM, respectively
(Figure 1C). Lenvatinib also inhibited FGF-2 induced pro-
liferation and tube formation of HUVECs with IC50 values
of 410 and 590 nM, respectively (Figure 1D).
Antiangiogenesis and antitumor activity of lenvatinib in
VEGF- and FGF-dependent angiogenesis models
We established tumor models in which the in vivo tumor
growth was promoted by VEGF- and FGF-induced angio-
genesis to evaluate both antiangiogenesis and antitumor
activity of lenvatinib in mice. Human pancreatic cancer
KP-1 cells exhibited a minimum angiogenic activity in the
mouse DAS assay (Figure 2A and Additional file 2A). KP-
1 cells were stably transfected to overexpress either human
VEGF121 (KP-1/VEGF) or mouse FGF-4 (KP-1/FGF)
(Additional file 2B and Additional file 3A). There was
no difference of in vitro growth rate between these
transfectants (data not shown). Conditioned medium
from KP-1/VEGF and KP-1/FGF cultures induced tube
formation of HUVECs in the sTF assay (Additional file
2C). Consistent with the sTF assay, in vivo angiogenesis
was induced by KP-1/VEGF and KP-1/FGF compared to
KP-1 mock (Figure 2A and Additional file 2A). Lenvatinib
at doses of 10 and 30 mg/kg significantly inhibited in vivo
angiogenesis in both the KP-1/VEGF and KP-1/FGF
models (Figure 2B), while sorafenib showed selective anti-
angiogenic activity in the KP-1/VEGF model at 100 and
300 mg/kg. This data suggested that lenvatinib inhibited
both VEGF- and FGF-induced angiogenesis in mice.
The in vivo tumor growth of KP-1/VEGF and KP-1/
FGF transfectants was faster than that of KP-1 mock in
nude mice (Additional file 3B), accompanied with selective
Figure 2 Effects of lenvatinib on in vivo angiogenesis induced by KP-1/VEGF and KP-1/FGF transfectants. (A) In vivo angiogenesis in
mouse DAS assay. Angiogenesis was induced by overexpressed human VEGF121 (KP-1/VEGF) or mouse FGF4 (KP-1/FGF) in human pancreatic
cancer KP-1 cells at the mouse dorsal skin. Representative photographs are shown. (B) Effect of lenvatinib and sorafenib on the VEGF- and
FGF-driven in vivo angiogenesis in mouse DAS assay. Compounds were administered orally once daily for 4 days at the indicated doses. Data are
the mean ± std. *: p < 0.05 and **: p < 0.01 compared to vehicle.
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genesis (Additional file 3A). Lenvatinib did not potently
inhibit the in vitro growth of KP-1/VEGF transfectants
(IC50: 19.6 μM). In the KP-1/VEGF xenograft model,
lenvatinib treatments at doses between 1 to 100 mg/kg
resulted in significant inhibitions of tumor growth
(Figure 3A). IHC analysis (CD31 staining) demonstrated
lenvatinib inhibited angiogenesis at 1 mg/kg (Figure 3A)
and resulted in 80% to 86% reduction of MVD com-
pared to the control group at doses of 1 to 100 mg/kg
(Additional file 4A). At a dose of 3 mg/kg, the inhibition
of VEGFR2 phosphorylation lasted for 6 hrs and at a
dose of 30 mg/kg, it was remarkably inhibited until
24 hrs after lenvatinib treatment (Additional file 4B).
Lenvatinib inhibited VEGF-induced tyrosine phosphor-
ylation of VEGFR2 in HUVECs with an IC50 value of
0.25 nM and also inhibited downstream signals, such as
the phosphorylation of extracellular signal-regulated
kinase (Erk)1/2 and Akt (Additional file 4C). These re-
sults indicated that lenvatinib inhibited VEGFR2 phos-
phorylation on tumor vessels in the KP-1/VEGF model.
Next, we examined the antitumor activity of lenvatinib
in advanced KP-1/VEGF transfectant models, in which
large tumors were treated with lenvatinib (Figure 3B).
Lenvatinib significantly inhibited tumor growth of KP-1/VEGF transfectants and had similar anti-tumor activity
against large and small tumors. In addition, the second
cycle of lenvatinib treatments resulted in a level of in-
hibitory activity similar to that seen in the first cycle
(Figure 3C), suggesting that KP-1/VEGF xenografts did
not acquire resistance to lenvatinib treatment. In the
KP-1/FGF xenograft models, lenvatinib at doses of 30
and 100 mg/kg resulted in a dose-dependent inhibition
of tumor growth (Figure 3D).
Antitumor activity of lenvatinib in various types of
human tumor xenograft models
Antitumor activity of lenvatinib was investigated using
seven human tumor xenograft models of melanoma
(MDA-MB 435), pancreatic (MIApaca-II), lung (H460),
ovarian (SK-OV-3), colorectal (Colo205), epidermoid
(A431) and prostate (DU145) cancers in nude mice
(Table 1). Treatment with lenvatinib at doses of 1 to
100 mg/kg resulted in a dose-dependent inhibition of
tumor growth in all seven tumor xenograft models and
significantly inhibited tumor growth in 5 of 7 models
even at 1 mg/kg. Lenvatinib at 100 mg/kg (maximum
tolerated dose (MTD)) caused tumor shrinkage of more
than 10% in 4 of 7 tumor xenograft models. Lenvatinib
did not show potent inhibitory activity against the
Figure 3 Antitumor activity of lenvatinib against the KP-1/VEGF and KP-1/FGF transfectants in nude mice. Lenvatinib was administered
orally twice daily, when tumor volumes reached approximately 200 mm3 (A,C,D). Each group consisted of 5 mice. Data are the mean ± std.
*p < 0.05 compared to vehicle. (A-C) the KP-1/VEGF xenograft model. (D) the KP-1/FGF xenograft model. (A) Antitumor activity of lenvatinib
against KP-1/VEGF xenografts. Lenvatinib was administered at 1–100 mg/day for 14 days. Tumor tissues were resected on day 26 for IHC analysis.
Tumor vessels were stained with anti-mouse CD31 antibody. Photographs were taken using a light microscope (x25) and representative images
are shown. (B) Antitumor activity of lenvatinib in the advanced KP-1/VEGF xenograft model. Lenvatinib was administered at 100 mg/kg for either
14, 18 or 14 days, when the tumor size reached 150, 650 and 1000 mm3, respectively. (C) Antitumor activity of lenvatinib with an interval of
treatments. Lenvatinib was administered at 100 mg/kg for 14 days in the 1st cycle and again given for 10 days in a 2nd cycle with 11 days
interval between the 1st and 2nd cycles. (D) Antitumor activity of lenvatinib in the KP-1/FGF xenograft model. Lenvatinib was administered at 30
and 100 mg/kg for 14 days.
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tolerated lenvatinib treatments well and only slight
losses of body weights (10%<) at a dose of 100 mg/kg
twice daily for 4 weeks was observed in 3 out of 7
models. These results indicated that lenvatinib had a
wide therapeutic window in VEGF-dependent tumor
models and caused tumor shrinkage at MTD dose in
more than a half of various types of human tumor xeno-
graft models.
IHC analysis of tumor vasculature (MVD and pericyte
coverage) as biomarkers associated with the antitumor
activity of lenvatinib
There are accumulating evidences that tumor vascula-
ture evaluated by MVD and % of pericyte coverage has
an impact on disease prognosis and/or acquired resist-
ance to antiangiogenesis therapy in cancer patients
[4,23]. Antitumor activity of lenvatinib was determined
in an extended panel of 19 human tumor xenograft
models (Figure 4A and Additional file 5) to explore
tumor vasculature (MVD and % of pericyte coverage) as
biomarkers to predict response to lenvatinib. Lenvatinibtreatment was done at a dose of 100 mg/kg, since we de-
tected tumor shrinkage in more than a half of 7 xeno-
graft models at this dose (Table 1). Lenvatinib treatment
resulted in tumor shrinkage in 8 tumor xenograft
models, which were designated the “sensitive” tumors
(ΔT/C < 0), while lenvatinib treatment caused slowing of
tumor growth in 10 tumor xenograft models and had no
effect in the SEKI model. These 11 tumors were desig-
nated as the “relatively resistant” tumors (ΔT/C > 0). We
next analyzed MVD and % of pericyte coverage at pre-
treatment (baseline) by IHC assay (CD31 for MVD and
αSMA for pericyte coverage) (Additional file 5). There
were significant associations of high MVD (p = 0.043)
and low % of pericyte coverage (p = 0.0078) with antitu-
mor activity of lenvatinib in the sensitive tumors com-
pared to the relatively resistant tumors (Figure 4B and
4C). To further investigate the relationship of antitumor
activity of lenvatinib to tumor vasculature, we performed
an analysis using vascular score (Figure 4D) based on
the sum of MVD score (ranging from 1 (low MVD) to 6
(high MVD)) and pericyte coverage score (ranging from
0 (high pericyte coverage) to 6 (low pericyte coverage))
Figure 4 Association of antitumor activity of lenvatinib with
tumor vasculature in 19 human tumor xenograft models.
Lenvatinib was administered orally twice daily for 7 days, when
tumor volumes reached approximately 100–300 mm3. Each group
consisted of 5 mice. (A) Antitumor activity of lenvatinib in 19 human
tumor xenograft models. The ΔT/C (%) was presented as a mean.
□: The lenvatinib-sensitive group; ■: the lenvatinib-relatively resistant
group. The relationship between the antitumor activity and MVD is
shown in (B), and that between the antitumor activity and the % of
pericyte coverage of vessels is shown in (C). Each symbol (○) indicates
the mean of MVD or pericyte coverage in each tumor xenograft model.
(D) Vascular score in the lenvatinib-sensitive and –relatively resistant
groups. The vascular score was the sum of the MVD and pericyte
coverage scores.
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between the sensitive and relatively resistant tumors
(p = 0.0004) with vascular score. These data suggested
that tumor vasculature (MVD and % of pericyte cover-
age) was the biomarker of the response to lenvatinib
and vascular score predicted antitumor activity of len-
vatinib in preclinical 19 xenograft models.
IHC analysis of MVD and % of pericyte coverage using
human tumor specimens
We examined MVD and % of pericyte-coverage using
human tumor tissues specimens (tissue micro-arrays) to
determine if vascular score was able to define tumor
vascular phenotypes in human cancer, as we did inhuman tumor xenograft models. We analyzed 18
different types of human primary tumor specimens
(Additional file 7) by IHC analysis (CD31 for MVD and
αSMA for % of pericyte coverate) (Figure 5A and 5B).
The median MVD ranged from 185.5 to 595.5 per mm2
in all types of human tumor specimens and tumors in
the kidney had the highest MVD (595.5 per mm2),
whereas the median pericyte coverage ranged from
4.9% to 29.6% in all types of human tumor specimens
and tumors in the liver had the lowest median pericyte
coverage (4.9%) (Additional file 8). To analyze MVD
combined with pericyte coverage, we performed vascular
score analysis using the sum of MVD and pericyte cover-
age scores (Additional file 6B). Tumors in the kidney and
stomach had the highest vascular scores at 11, followed
by those in the liver and lymphoma at 10 and in the
thyroid and lung at 9 (Figure 5C). These results sug-
gested that IHC analyses of MVD and % of pericyte
coverage with vascular score were considered as bio-
markers for searching target types of cancers for lenva-
tinib and responses to lenvatinib treatments based on
tumor vasculature.
Preclinical correlative analysis of mRNA expression of
genes related to angiogenesis with antitumor activity of
lenvatinib
We performed qPCR analysis of gene expression related
to angiogenesis within tumor tissues from a panel of 19
human tumor xenograft models, in which antitumor activ-
ity of lenvatinib was determined (Figure 4A). We associ-
ated mRNA expression levels with antitumor activity of
lenvatinib in the sensitive and relatively-resistant sub-
groups (Additional file 1A). Among the 59 genes exam-
ined, expression levels of high EGFR (p = 0.018, fold differ-
ence of median = 6.867) and low PlGF (p = 0.027, fold
difference of median = 0.554) were significantly associ-
ated with antitumor activity in the sensitive sub-group.
We also correlated mRNA expression levels with ΔT/C
(Additional file 1B). High EGFR and KITLG expression
levels (p = 0.014, 0.023 and r = 0.568, 0.533, respectively)
and low PDGFRA and FGF7 expression levels (p = 0.010,
0.049 and r = −0.590, 0.470, respectively) were correlated
with small ΔT/C.
Discussion
In this study, we determined the inhibitory activity (Ki)
of lenvatinib against VEGFR1-3, FGFR1-3, RET and KIT.
Lenvatinib inhibited VEGF- and FGF2-driven proliferation
and tube formation of HUVECs in vitro and also in vivo
angiogenesis in mouse DAS assays using the KP-1/VEGF
and KP-1/FGF, in which angiogenesis was induced by
over-expressed angiogenic factors. Lenvatinib significantly
inhibited the in vivo growth of KP-1/VEGF tumor, which
was enhanced by VEGF-driven angiogenesis, accompanied
Figure 5 IHC analysis of tumor vasculature in 18 different types of human tumor specimens. Microvessel density (MVD), pericyte coverage
and vascular scores were determined with IHC analysis by staining CD31 and αSMA among 18 types of human tumor specimens. Analysis was
performed as described in materials and methods. Bars (red) indicated median values for MVD or % of pericyte coverage of each type of tumors.
(A) MVD. (B) % of pericyte coverage. (C) Summary of MVD, pericyte coverage and vascular score.
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significant antitumor activity from 1 mg/kg to 100 mg/kg
in KP-1/VEGF models. This data suggested lenvatinib
showed wide therapeutic windows in the highly VEGF-
dependent model. Antitumor activity of lenvatinib was
highly associated with vascular score (combined scores
of high MVD and low pericyte coverage) in a panel of
19 human tumor xenograft models consisting of variety
of cancer types.
Lenvatinib showed significant antiangiogenesis activity
(decrease of MVD) in the KP-1/VEGF xenograft model
at 1 mg/kg and at 10 mg/kg against VEGF-driven angio-
genesis in KP-1/VEGF DAS assays. At 10 mg/kg, lenvati-
nib also inhibit FGF-driven angiogenesis in KP-1/FGF
DAS assays. Sorafenib (100 mg/kg) inhibited VEGF-driven
angiogenesis in the DAS assay, but did not inhibit FGF-
driven in vivo angiogenesis, indicating that inhibition of
VEGF signaling was not enough to inhibit FGF-driven
angiogenesis in the KP-1/FGF DAS assay. FGF and VEGF
synergistically [35] promote multi-step of angiogenesis.
Even low levels of VEGF may promote FGF-driven angio-
genesis in the KP-1/FGF DAS model. Since lenvatinib
could inhibit both VEGF and FGF signaling, lenvatinib
might effectively inhibited FGF-driven in vivo angiogenesis
in this model. Among the FGFRs, FGFR1 and FGFR2 are
likely to have the greatest impact on angiogenesis. In cell
assays, sorafenib has a less potent effect on FGFR-driven
proliferation (i.e. the IC50 value is 2 μM) [36] than does
lenvatinib (the IC50 value is 410 nM). This less activity of
sorafenib reported in cell assays might contribute to less
in vivo antiangiogenesis activity in the KP-1/FGF model.
VEGF-C is involved in lymphangiogenesis and lymphatic
metastasis via VEGFR3 signaling [37,38] and stem cell
factor (SCF) is an angiogenic factor via KIT signaling
[39]. Lenvatinib inhibited SCF-induced angiogenesis
and VEGF-C-induced lymphatic metastasis by inhibit-
ing KIT and VEGFR3 [26,30]. A pan-inhibitory activity
of lenvatinib against the family of multiple split kinases
might contribute to lenvatinib’s broad-spectrum antitu-
mor activity based on the inhibition of angiogenesis
driven by multiple angiogenic factors such as VEGFA,
SCF, VEGF-C and FGF.
Vascular score, which was the sum of MVD and peri-
cyte coverage scores was used to analyze the associ-
ation of tumor vasculature with the sensitivity of tumor
models to lenvatinib treatments. There was only one
model (HMV-1) with more than vascular score 8 among
the 11 relatively-resistant models, but 7 out of 8 models
in the sensitive group had vascular scores more than 8
(Figure 4D). This result suggested that vascular score
predicted tumor shrinkage with lenvatinib treatment in
preclinical 19 human tumor xenograft models. We used
αSMA staining, to determine pericyte coverage in this
study. But αSMA is a marker of smooth muscle cell andit may be worth to test other pericyte markers, such as
NG-2, to confirm roles of pericyte in sensitivity to len-
vatinib treatment in further study. Recently Smith et al.
reported that IHC analysis with MVD and % of αSMA
positivity identified tumor types with either tumor ves-
sel types or stromal vessel types as phenotypes of tumor
vasculature. Tumor vessel types in RCC, HCC, thyroid
cancer are respond, but stromal vessel types in CRC,
breast cancer, prostate cancer are refractory to a single
anti-VEGF therapy [40]. Studies might be expected to
confirm vascular score consisted of MVD and pericyte
coverage as potential predictive biomarkers for the se-
lection of patients responsive to antiangiogenic therapy.
Since there is a large degree of heterogeneity of tumor
vasculature even in each cancer type, the association of
vascular score with sensitivity to antiangiogeninc ther-
apy need to be further investigated in a larger group of
tumor samples in each cancer types.
In IHC analysis of human tumor specimens, tumors in
the kidney (renal cell carcinoma) had the highest MVD
and the tumors in the liver (the majority was hepatocel-
lular carcinoma (HCC)) had the lowest pericyte coverage
among the 18 primary tumor types assayed. The highest
vascular score was 11 for the RCC and tumors in the
stomach (the majority was adenocarcinoma), followed by
10 for the lymphoma and HCC, and 9 for the thyroid
(the majority was papillary thyroid cancer) and lung
(non small cell lung cancer). RCC, HCC and thyroid can-
cer have been approved for treatment with VEGFR2 TKIs
such as sunitinib (RCC), sorafenib (RCC, HCC), pazopa-
nib (RCC), axitinib (RCC) or vandetanib (MTC). In this
study, the colon and breast tumors had lower vascular
scores. Bevacizumab was approved for CRC and breast
cancer only in combination therapy with cytotoxic agents;
and regorafenib and aflibercept [41] were also approved
for CRC in combination with cytotoxic agents. Vascular
scores might be useful when evaluating the indication for
mono- or combo-therapy with anti-VEGF therapy.
We measured the mRNA expression levels of 59 genes
related to angiogenesis in xenografted tumors with qRT-
PCR by focusing on RTKs and their ligands (Additional
file 1). High EGFR and low PlGF mRNA expression
levels were associated with the sensitive group to lenva-
tinib treatments, and high expression levels of EGFR and
KITLG mRNA and low expression levels of FGF7 and
PDGFRA mRNA were correlated with smaller ΔT/C. The
EGFR signaling pathway induced VEGF expression [42]
and synergistic effects of combination therapies with
EGFR inhibitors and VEGFR2 inhibitors were reported
[43]. In the sTF assay, we stimulated HUVEC by using
VEGF with EGF, because capillary-like-network formation
was more constantly induced by the additional use of
EGF. EGF may be involved in cross-talk with VEGF signal-
ing, besides inducing VEGF expression.
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We showed that lenvatinib was an angiogenesis inhibitor
targeting VEGFR2 and FGFR and showed antitumor ac-
tivity in a broad spectrum of tumor xenograft models
and vascular score consisted of high MVD and low peri-
cyte coverage at pretreatment was the potential predict-
ive biomarker of lenvatinib in preclinical models. The
roles of tumor vasculature and vascular score as a pre-
dictive biomarker to lenvatinib treatment are warranted
for further examination in clinical settings.Additional files
Additional file 1: mRNA expression levels of 59 genes related to
angiogenesis were associated with the antitumor activity of
lenvatinib in a panel of human tumor xenograft models shown in
Figure 4A. We calculated ΔCT values for sample-to-sample normalization
based on the mean CT values of five endogenous controls (ACTB
(Hs99999903_m1), B2M (Hs99999907_m1), GAPDH (Hs99999905_m1), HMBS
(Hs00609297_m1), HPRT1(Hs99999909_m1)). Fold changes were calculated
after the 2-ΔCT transformation into linear space. mRNA expression levels
were correlated to anti-tumor activity in xenograft model based on ΔT/C for
correlation analysis and also associated with tumor response among
sensitive and resistant subgroup in a panel of human tumor xenograft
models divided into sensitive (ΔT/C < 0) and resistant (ΔT/C > 0) subgroups.
Statistical analysis (wilcox-test and spearman correlation) was performed
on the ΔCT values. Results were considered significant at p < 0.05.
(A) Correlation analysis, (B) Fold difference of expression levels among
relatively resistance and sensitive subgroup. Fold difference was show
as median expression levels of sensitive subgroup divided by those of
relatively resistant subgroup.
Additional file 2: Enhanced angiogenic activity of KP-1
transfectants over-expressing VEGF (human VEGF121) or FGF
(mouse FGF-4) in vitro and in vivo angiogenesis assay. (A) In vivo
angiogenesis assay in mouse Dorsal Air Sac assay with KP-1 transfectants:
Experiments were performed as described in materials and methods.
Data are the average ± std. (B) VEGF ELISA assay: Supernatants were
collected and the amounts of VEGF secreted from KP-1/VEGF determined
using a VEGF ELISA Kit (Immuno-Biological Laboratories) in both nor-
moxic (20% O2) and hypoxic (2% O2) condition. (C) Sandwich tube for-
mation (sTF) assay using condition medium (CM) from KP-1 transfectants:
sTF assay was performed using CM of KP-1 transfectants as described in
materials and methods.
Additional file 3: Analysis of KP-1 xenpgrafts over-expressing either
VEGF or FGF models in nude mice. (A) qRT-PCR analysis of
over-expression of human VEGF121 or mouse FGF4 within xenografted
KP-1 transfectants. KP-1 transectants were orthotopically implanted,
grown at the pancreas and then resected at the size of tumor volumes
around 200 –600 mm3 (n = 4). RT-PCR; Total RNA was extracted with
ISOGEN reagent (Nippongene) and cDNA was synthesized by
SUPERSCRIPT first-strand synthesis systems (GIBCO BRL) with 2 mg of total
DNA. PCR reaction was performed using themalcyclaer (Takara) and PCR
products were electrophoresis using 2% of agarose gel and visualized
with ethidium bromides. Primer information was available if requested.
(B) Enhanced s.c. tumor growth of KP-1/VEGF and KP-1/FGF transfectants
compared to KP-1 mock transfectants. Each group consisted of 5 mice.
Data are the average ± std. dev. *p < 0.05 compared to KP-1 mock
transfectants. (C) IHC analysis with H&E (upper panel) and with CD31
staining (lower panel) of endothelial cells. KP-1 transectants were
orthotopically implanted and grown at the pancreas. Tumor tissues was
resected 42 days after inoculation and IHC analysis was performed as
described in materials and methods. Representative photographs were
shown.
Additional file 4: Effects of lenvatinib on MVD in nude mice and on
phosphorylation of VEGFR2 in KP-1/VEGF transfectant models andin HUVEC in vitro. (A) Effects of lenvatinib on MVD within KP-1/VEGF
xenografted tumors. Lenvatinib was administered orally twice daily at
indicated doses. Tumor tissues were resected after 14 days treatment. IHC
analysis of MVD was performed with anti-mouse CD31 antibody, as de-
scribed in materials and methods. Each group consisted of 5 mice. Data
are the average ± std. **p < 0.01 compared to vehicle. (B-C) Western blot-
ting (WB) analysis for phosphorylated proteins. (B) Effects of lenvatinib on
phosphorylation of VEGFR2 within KP-1/VEGF xenografted tumors. Lenva-
tinib was administered at either 3 or 30 mg/kg in mice (n = 3) bearing
KP-1/VEGF xenografted tumors. Tumors were resected at indicated times
after lenvatinib administrations. Tumor was crushed by homogenizer with
lysis buffer including phosphatase inhibitor and then prepared adequate
concentration of lysate protein was subjected to
SDS-PAGE. KP-1/VEGF cells do not express VEGFR2 (data not shown). (C)
Western blotting analysis of VEGF-stimulated phosphorylation of VEGFR2
and downstream molecules in HUVECs. HUVECs were grown to
subconfluence and then starved with human endothelial serum-free
medium (SFM) basal medium containing 0.5% FBS for 24 hrs. HUVECs
were treated with the indicated concentrations of lenvatinib for 60 min,
followed by VEGF stimulation (20 ng/mL) for 5 min. Primary antibodies
against VEGFR2, phospho-VEGFR2, Erk1/2, phospho-Erk1/2, Akt and
phospho-Akt (Cell Signaling Technology; 1:1000) and the secondary anti-
body, anti-Rabbit IgG (H&L) HRP-linked antibody (Cell Signaling Technology;
1:1000) were used. The blots were developed with SuperSignal West Pico
chemiluminescent substrate (Pierce). Immunoreactive bands were visualized
by chemiluminescence with an Image Master™ VDS-CL detection system
(Amersham Pharmacia Biotech).
Additional file 5: Summary of antitumor activity of lenvatinib and
tumor vasculature in a panel of human tumor xenograft models in
nude mice. Lenvatinib was administered orally twice daily for
7 days at 100 mg/kg. Each group consisted of 3–6 mice. IHC analysis of
microvessel density (MVD) and % of pericyte coverage were performed
by staining CD31 and aSMA. ΔT/C (%) was shown as a mean and both
MVD and pericyte coverage were shown as a median. Scoring of
microvessel density (MVD) and pericyte coverage was based on a table
as shown in Additional file 6A. Vascular scores were the sum of MVD and
pericyte coverage scores. Antiangiogenesis activity was show
as % of means of MVD and pericyte coverage at post-treatment (day 8)
compared to those at pretreatment.
Additional file 6: Scoring for microvessel density (MVD) and % of
pericyte coverage by IHC analysis of with staining CD31 and aSMA
based on the median values of each group analysis. Analysis was
performed as descried in materials and methods. (A) Scores for 19
human tumor xenograft models, (B) Scored for 18 types of tumor tissues
specimens.
Additional file 7: Summary of human tumor specimens among 18
different types. ad-ca; adenocarcinoma, rcc; renal cell carcinoma, scc;
squamous cell carcinoma.
Additional file 8: IHC Analysis for Microvessel density (MVD) and %
of pericyte covered vessels in human tumor specimens with MVD
and pericyte coverage scores. MVD and pericyte coverage scores
(Additional file 6B) were based on the median values of analysis from
each type of tumor tissue specimens.
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